ArticleFrontiers in microbiology2026
Effect of Xiaoqinglong decoction on gut-lung axis microbiota in allergic rhinitis mice.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to characterize the effects of Xiaoqinglong decoction (XQLD) on the microbiota of the gut-lung axis at three key sites-the nasal cavity, lungs, and gut-in Allergic rhinitis (AR) mice, with particular attention to site-specific response patterns and their potential links to AR disease resolution. Methods: An ovalbumin-induced AR mouse model was established, with mice assigned to control, AR, loratadine, and XQLD groups. Intervention outcomes were assessed via behavioral observation, ELISA, histopathology, and 16S rRNA gene sequencing, followed by correlation analysis. Results: Compared with the AR group, XQLD significantly reduced nasal symptoms, serum OVA-sIgE and IL-4 levels, and nasal mucosal injury. AR induction markedly altered the nasal and gut microbiota, whereas the lung microbiota remained relatively stable. XQLD significantly increased nasal Conclusion: XQLD differentially modulates the gut-lung axis microbiota in AR mice, with the most marked changes observed in the gut, which may correlate with its therapeutic effects and merit further mechanistic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.